Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Share-based Compensation (2019 - 2026)

Immunovant filings provide 7 years of Share-based Compensation readings, the most recent being $12.7 million for Q4 2025.

  • Quarterly Share-based Compensation rose 9.12% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.3 million through Dec 2025, up 18.52% year-over-year, with the annual reading at $49.5 million for FY2025, 20.36% up from the prior year.
  • Share-based Compensation hit $12.7 million in Q4 2025 for Immunovant, down from $13.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $18.5 million in Q2 2025 and bottomed at $3.9 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $10.4 million, with a median of $10.4 million recorded in 2023.
  • The largest annual shift saw Share-based Compensation surged 198.26% in 2021 before it tumbled 36.39% in 2023.
  • Immunovant's Share-based Compensation stood at $10.2 million in 2021, then decreased by 12.33% to $8.9 million in 2022, then grew by 14.75% to $10.2 million in 2023, then grew by 14.01% to $11.7 million in 2024, then rose by 9.12% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Share-based Compensation are $12.7 million (Q4 2025), $13.4 million (Q3 2025), and $18.5 million (Q2 2025).